Title Image

Our Facilities

Production Facilities Overview

Rameda operates three fully independent factories at its plant in Cairo’s Sixth of October Industrial Zone. The purpose-built factories were designed by V-Konsult, a German engineering company, and built by British Carter Construction Ltd. In 2012, Rameda collaborated with M+W Process Industries GmbH, a global engineering and construction company offering complete process and facilities solutions for the pharmaceutical industry, to redesign the plant production areas and ensure GMP compliance.

In 2017, Rameda embarked on a new expansion drive that is poised to grow production capacity at its facilities by an additional 40%, which has been completed in 2019.

Together, these facilities house a total of 20 production lines, deploying best-in-class manufacturing processes and technology. All of Ramada’s facilities are ISO-certified.


Fully independent factories

40,000 sqm

Land area

38,000 sqm

Built-up area

c7,000 sqm

Dedicated production facility

Warehousing Facilities

Rameda has a state-of-the-art, purpose-built warehousing facility that includes the following:

General storage space spanning over 3,078 sqm of air-conditioned space, storing approximately 10,000 pallets.

1,650 sqm of storage space dedicated to housing cephalosporin products, with a total capacity of 1,600 pallets.

1,000 sqm of storage space dedicated to housing penicillin products, with a total capacity of over 1,510 pallets.

Four fridges with temperatures set to 5 (± 3) degrees celsius and one cool room set at 15 (±3) degree Celsius.

Production Lines

Rameda specializes in the manufacturing of human and veterinary pharmaceutical products. Its plant is comprised of three standalone factories located in the same industrial complex.

The first factory houses five production areas that include 15 production lines capable of producing a wide range of general medicinal forms, namely: eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials. The second factory houses three production lines that manufacture cephalosporin products. The third factory includes two production lines dedicated for penicillin products.

Factory 1

Eye Drops Production Area

Rameda began producing eye drops in 1998 and renovated its production area in 2013. In 2017, the Group added lidocaine preparation to the area. The eye drop production line occupies an area of 710 sqm with an annual production capacity of 16.3 million bottles.

Oral Liquids & Suspensions Area

Rameda began producing oral liquids in 1993 and renovated its oral liquids production area in 2010 and again in 2013, where the area was upgraded, machinery repaired and an automated packaging machine was added. Comprising three production lines with a combined annual capacity of 42.9 million bottles, the oral liquids & suspension area occupies a total of 769 sqm.

Lyophilized Injectables

Rameda added two new lyophilized lines in November 2019, making Rameda one in few companies in the market with lyophilized manufacturing capabilities.

Solid Dosage Area

Rameda began producing solid dosage products in 1993, with a complete redesign and upgrade of its manufacturing lines completed in 2019. The solid dosage area houses a total of 7 production lines with the capability to produce medicine across multiple dosage forms, including tablets, capsules, macro dosing bottles and sachets.

Blow-Fill-Seal Production Area

Rameda began producing BFS products in 2015 after installing a production line with plastic ampoule capabilities in 2014. An additional BFS line was introduced in April 2019, bringing up its production capacity to 109 million ampoules per year. The BFS production area occupies a total of 468 sqm.

Factory 2

Dedicated to the manufacturing of cephalosporin products

The factory is comprised of two production areas:
The first area houses two manufacturing lines to produce cephalosporins vials in addition to a dedicated area for the powder macro dosing line.

Factory 3

Dedicated to the manufacture of penicillin products

The area produces penicillin in tablet, capsule, and powder macro-dosing forms.